Publications by authors named "Adam Keeton"

Claim this Profile
E
Exploring dual inhibitors Carbonic Anhydrases and Phosphodiesterase 5 as potential agents for treatment Alzheimer's disease.
Alessia Costa, Gustavo Provensi, Costanza Titi, Manuela Leri, Monica Bucciantini, Adam B Keeton

Eur J Med Chem· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and Characterization of Novel Pan-RAS Inhibitor Loaded Ultraflexible Liposomes for the Topical Prevention or Treatment of Skin Melanoma.
Shivani A Dave, Adam B Keeton, Gary A Piazza, Anthony J Di Pasqua

Pharm Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Disulfiram-Loaded Metal-Organic Nanoparticles Inhibit Tumor Growth and Induce Immunogenic Cell Death of Triple-Negative Breast Cancer Cells.
Chung-Hui Huang, Xuejia Kang, Lang Zhou, Junwei Wang, Shuai Wu, Adam B Keeton

Pharmaceutics· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models.
Daniela D De Nobrega, Logan C Eiler, Parmanand Ahirwar, Sonika Nallapu, Urvi P Rawal, Adam B Keeton

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclic nucleotide phosphodiesterases as drug targets.
Michy P Kelly, Viacheslav O Nikolaev, Leila Gobejishvili, Claire Lugnier, Christian Hesslinger, Adam B Keeton

Pharmacol Rev· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Celecoxib Derivative, RF26, Blocks Colon Cancer Cell Growth by Inhibiting PDE5, Activating cGMP/PKG Signaling, and Suppressing β-catenin-dependent Transcription.
Sara Sigler, Mohammad Abdel-Halim, Reem K Fathalla, Luciana Madeira Da Silva, Adam B Keeton

Anticancer Agents Med Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Jeremy B Foote, Tyler E Mattox, Adam B Keeton, Xi Chen, Forrest T Smith

Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models.
Daniela De Nobrega, Logan C Eiler, Parmanand Ahirwar, Urvi P Rawal, Chelsea L Crawford, Adam B Keeton

bioRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, Julienne L Carstens, Jeremy B Foote, Adam B Keeton

Mol Cancer· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer.
Jeremy B Foote, Tyler E Mattox, Adam B Keeton, Xi Chen, Forrest Smith

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma.
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, Julienne L Carstens, Jeremy B Foote, Adam B Keeton

bioRxiv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Non-Cyclooxygenase Inhibitory Derivative of Sulindac Inhibits Breast Cancer Cell Growth In Vitro and Reduces Mammary Tumorigenesis in Rats.
Heather N Tinsley, Bini Mathew, Xi Chen, Yulia Y Maxuitenko, Nan Li, Adam B Keeton

Cancers (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphodiesterase 10A (PDE10A) as a novel target to suppress β-catenin and RAS signaling in epithelial ovarian cancer.
Rebecca M Borneman, Elaine Gavin, Alla Musiyenko, Wito Richter, Kevin J Lee, Adam B Keeton

J Ovarian Res· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Alexander B Coley, Antonio Ward, Adam B Keeton, Xi Chen, Yulia Maxuitenko

Adv Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The path to the clinic: a comprehensive review on direct KRAS inhibitors.
Albert K Kwan, Gary A Piazza, Adam B Keeton, Caio A Leite

J Exp Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Colon Tumorigenesis in Mutant Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic β-Catenin.
Kevin J Lee, Wen-Chi L Chang, Xi Chen, Jacob Valiyaveettil, Veronica Ramirez-Alcantara, Adam B Keeton

Cancer Prev Res (Phila)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel thiazolidine derivatives as potent selective pro-apoptotic agents.
Donia E Hafez, Eman Hafez, Islam Eddiasty, Shou-Ping Shih, Leng-Chiang Chien, Adam B Keeton

Bioorg Chem· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity.
Mohammad Abdel-Halim, Sara Sigler, Nora A S Racheed, Amr Hefnawy, Reem K Fathalla, Adam B Keeton

J Med Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Isatin-Indole Conjugates: Synthesis, Characterization, and a Plausible Mechanism of Their in vitro Antiproliferative Activity.
Reem I Al-Wabli, Aliyah A Almomen, Maha S Almutairi, Adam B Keeton, Gary A Piazza

Drug Des Devel Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors.
Mohammad Abdel-Halim, Heather Tinsley, Adam B Keeton, Mohammed Weam, Noha H Atta

Bioorg Chem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.
Antonio B Ward, Adam B Keeton, Xi Chen, Tyler E Mattox, Alex B Coley

MedComm (2020)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity.
Gary A Piazza, Antonio Ward, Xi Chen, Yulia Maxuitenko, Alex Coley, Adam B Keeton

Drug Discov Today· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the Lysophosphatidylinositol Transporter ABCC1 Reduces Prostate Cancer Cell Growth and Sensitizes to Chemotherapy.
Aikaterini Emmanouilidi, Ilaria Casari, Begum Gokcen Akkaya, Tania Maffucci, Luc Furic, Adam B Keeton

Cancers (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors.
Ahmed K ElHady, Shou-Ping Shih, Yu-Cheng Chen, Yi-Chang Liu, Nermin S Ahmed, Adam B Keeton

Bioorg Chem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.
Tyler E Mattox, Xi Chen, Yulia Y Maxuitenko, Adam B Keeton, Gary A Piazza

Int J Mol Sci· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis